ArticlePloS one2025
The role of albumin-corrected anion gap as a predictor of all-cause mortality in patients with Sepsis-AKI: A propensity score-matched cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Albumin-corrected anion gap and 28-/90-day mortality in cirrhotic patients with invasive fungal infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Machine learning model for predicting the risk of AKI in early hemodynamically stable sepsis patients: a study based on the MIMIC IV database.Frontiers in medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe potential association between albumin-corrected anion gap at admission and prognosis in patients with sepsis-induced AKI remains uncertain. The purpose of this study was to explore the prognostic value of ACAG on mortality in patients with Sepsis-AKI.
methodsData for this retrospective study were obtained from the MIMIC IV2.2 database. We used propensity score matching (PSM) and Cox proportional hazards regression analysis to evaluate the correlation between the ACAG and clinical outcomes in patients with Sepsis-AKI. Propensity score matching (PSM) analysis was conducted to minimize bias. Receiver operating characteristic curves were generated for albumin, AG, and ACAG, and comparisons of the areas under the ROC curves were made. Decision curve analysis (DCA) was carried out to assess the net benefit of ACAG.
resultsAccording to the screening criteria, we identified a cohort of 2387 patients diagnosed with Sepsis-AKI. When comparing the normal-ACAG group(12-20 mmol/L) to the high-ACAG group(>20mmol/L)), it was found that the high-ACAG group exhibited longer stays in the ICU(5 days vs.4 days, P = 0.023) and higher hospital mortality rate(48.5% vs. 20.2%, P < 0.001). After matching, Cox regression analysis results showed that the high-ACAG group exhibited higher risk of hospital mortality (HR = 1.80, 95%CI: 1.27-2.56, P < 0.001). The area under the curve (AUC) values of ACAG was 0.697 (after PSM), which was significantly higher than those of albumin or AG. ACAG also had the highest Youden's index and the largest net benefit range according to the decision curve analysis (DCA).
conclusionElevated serum ACAG (>20 mmol/L) is an independent risk factor for all-cause hospital mortality in patients with Sepsis-AKI. ACAG can be a new and easily acquired indicator that can provide new ideas for clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.